- Hepatitis B is one of the most common infectious diseases in the world, with 350 million people worldwide being chronically infected – this compares with 33 million people living with HIV infection – yet there remains a lack of reliable resources for hepatitis B patients and caregivers
- PATH B – “Patients and Professionals Acting Together for Hepatitis B” (http://www.pathb.com/) – is a new programme that provides information and tools to guide patients through their journey with chronic hepatitis B from diagnosis to long-term disease management
Paris, France, 21 October 2011 – A pioneering educational resource, designed to improve the lives of people living with chronic hepatitis B, was launched today at an annual conference organised by Bristol-Myers Squibb in Hong Kong where 26 patient advocacy groups from 14 countries and regions gathered to discuss viral hepatitis.
The PATH B (“Patients and Professionals Acting Together for Hepatitis B”) programme was developed by an international advisory board comprising people living with hepatitis B, as well as patient advocacy group representatives and leading hepatologists from across Europe. This programme is provided as an educational service by the World Hepatitis Alliance (WHA) and The European Liver Patients Association (ELPA). The programme was organised and funded by Bristol-Myers Squibb.
You can find the full press release and the backgrounder here:
PATH B Backgrounder